<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583216</url>
  </required_header>
  <id_info>
    <org_study_id>ATADEK-2017/10</org_study_id>
    <nct_id>NCT03583216</nct_id>
  </id_info>
  <brief_title>Comparison of Factor XII Levels in Gestational Diabetic and Healthy Pregnancies</brief_title>
  <official_title>Comparison of Factor XII Levels in Gestational Diabetic and Healthy Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Factor XII levels in gestational diabetic and healthy pregnancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty singleton term pregnant women with a diagnosis of Type I, Type II or gestational
      diabetes and thirty singleton uncomplicated term healthy pregnant women will be included in
      our study. Our study will be performed at Istanbul Acibadem Maslak Hospital, Turkey. Blood
      will be drawn from each patient when they are hospitalized and before they deliver either
      vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will
      contain 4 ml blood. Blood will be transferred to the lab immediately and will be centrifuged.
      The supernatant will be stored at -80°C. When the anticipated number of samples are completed
      Factor XII levels will be calculated in each sample.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Factor XII level</measure>
    <time_frame>Blood will be drawn when the patient is hospitalized before they deliver.</time_frame>
    <description>The primary outcome is to evaluate Factor XII level in diabetic pregnancies. If the investigators can prove that Factor XII, which has a mitogenic activity and can increase the risk for thrombosis, increases more in diabetic pregnancies in the future usage of Factor inhibitors may reduce macrosomia, thrombosis and the complications due to these conditions in diabetic pregnancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macrosmia</measure>
    <time_frame>Blood will be drawn when the patient is hospitalized before they deliver.</time_frame>
    <description>The secondary outcome is to prove that the increase of Factor XII level is higher diabetic pregnancies and this increase might have an effect on macrosomia.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetic Pregnancy</condition>
  <condition>Pregnancy Related</condition>
  <condition>Complement System; Disorder</condition>
  <arm_group>
    <arm_group_label>Diabetic pregnancy</arm_group_label>
    <description>Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic pregnancy</arm_group_label>
    <description>Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diabetic pregnancy</intervention_name>
    <description>Blood samples will be drawn before delivery to evaluate Factor XII level.</description>
    <arm_group_label>Diabetic pregnancy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-diabetic pregnancy</intervention_name>
    <description>Blood samples will be drawn before delivery to evaluate Factor XII level.</description>
    <arm_group_label>Non-diabetic pregnancy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      8ml of blood samples will be drawn from each participitant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        30 Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes and 30
        non-diabetic pregnant patients will be included in our trial.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term pregnancy

          -  Pregnant patients with a diagnosis of Type I diabetes

          -  Pregnant patients with a diagnosis of Type II diabetes

          -  Pregnant patients with a diagnosis of Gestational diabetes

          -  Non-diabetic pregnancies

          -  Uncomplicated pregnancies

        Exclusion Criteria:

          -  Preterm pregnancy

          -  Postterm pregnancy

          -  Pregnant patients with a diagnosis of systemic diseases other than diabetes

          -  Complicated pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mete Gungor, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem MAA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Acibadem Maslak Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Sariyer</state>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Schousboe I. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. Biochem Pharmacol. 2008 Mar 1;75(5):1007-13. Epub 2007 Oct 7. Review.</citation>
    <PMID>17996217</PMID>
  </reference>
  <reference>
    <citation>Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, Frère JM, Feron O, Dogné JM, Dessy C, Vanhamme L, Godfroid E. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009 Oct 26;206(11):2381-95. doi: 10.1084/jem.20091007. Epub 2009 Oct 5.</citation>
    <PMID>19808248</PMID>
  </reference>
  <reference>
    <citation>Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):234-50. Review.</citation>
    <PMID>19689262</PMID>
  </reference>
  <results_reference>
    <citation>Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood. 2012 Nov 22;120(22):4296-303. doi: 10.1182/blood-2012-07-292094. Epub 2012 Sep 19. Review.</citation>
    <PMID>22993391</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>December 26, 2018</last_update_submitted>
  <last_update_submitted_qc>December 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Esra Ozbasli</investigator_full_name>
    <investigator_title>Ass. Prof.</investigator_title>
  </responsible_party>
  <keyword>Diabetic pregnancies, Factor XII</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy in Diabetics</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

